Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases

Although daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, and dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, have been approved for the treatment of renal anemia in Japan, their efficacy and safety for patients aged 80 years or older with low-risk myelodysplastic syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Satoshi, Horiuchi, Takahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048526/
https://www.ncbi.nlm.nih.gov/pubmed/36975732
http://dx.doi.org/10.3390/hematolrep15010019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048526/
https://www.ncbi.nlm.nih.gov/pubmed/36975732
http://dx.doi.org/10.3390/hematolrep15010019

Ejemplares similares